Please login to the form below

Not currently logged in
Email:
Password:

study

This page shows the latest study news and features for those working in and with pharma, biotech and healthcare.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan and partner Molecular Partners say a pair of two studies of abicipar show that the drug is non-inferior to monthly dosing with Roche and Novartis’blockbuster Lucentis (ranibizumab) when ... Both studies will continue for another year. Lucentis

Latest news

More from news
Approximately 5 fully matching, plus 1,293 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 329 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 54 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 30 fully matching, plus 356 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics